Fulcrum Therapeutics, Inc.
US ˙ NasdaqGM ˙ US3596161097

SecurityFULC / Fulcrum Therapeutics, Inc.
InstitutionFmr Llc
Latest Disclosed Ownership1,724,014 shares
Ownership 2.76%
Fmr Llc ownership in FULC / Fulcrum Therapeutics, Inc.

2024-10-07 - Fmr Llc has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 1,724,014 shares of Fulcrum Therapeutics, Inc. (US:FULC). This represents 2.762 percent ownership of the company. In their previous filing dated 2024-02-09 , Fmr Llc had reported owning 5,684,615 shares, indicating a decrease of -69.67 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2024-10-07 2024-10-07 13G/A 5,684,615 1,724,014 -69.67 2.76 -69.96
2024-02-09 2024-02-09 13G/A 5,233,725 5,684,615 8.62 9.20 -8.54
2023-02-09 2023-02-09 13G/A 6,082,317 5,233,725 -13.95 10.05 -32.97
2022-02-09 2022-02-09 13G/A 6,044,763 6,082,317 0.62 15.00 0.00
2021-09-10 2021-09-10 13G/A 1,749,736 6,044,763 245.47 15.00 135.43
2021-02-08 2021-02-08 13G/A 1,700,751 1,749,736 2.88 6.37 -12.56
2020-02-07 2020-02-07 13G 1,700,751 7.29

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F FULCRUM THERAPEUTICS COM 359616109 61,041 53,350 693.67 468 444.19 0.0000
2026-02-17 2025-12-31 13F FULCRUM THERAPEUTICS COM 359616109 7,691 341 4.64 87 28.36 0.0000
2025-11-13 2025-09-30 13F FULCRUM THERAPEUTICS COM 359616109 7,350 383 5.50 68 42.55 0.0000
2025-08-14 2025-06-30 13F FULCRUM THERAPEUTICS COM 359616109 6,967 2,649 61.35 48 291.67 0.0000
2025-05-12 2025-03-31 13F FULCRUM THERAPEUTICS COM 359616109 4,318 -86,147 -95.23 12 -97.18 0.0000
2025-02-13 2024-12-31 13F FULCRUM THERAPEUTICS COM 359616109 90,465 -1,633,550 -94.75 425 -93.09 0.0000
2024-11-13 2024-09-30 13F FULCRUM THERAPEUTICS COM 359616109 1,724,015 -3,605,931 -67.65 6,155 -81.38 0.0004
2024-08-13 2024-06-30 13F FULCRUM THERAPEUTICS COM 359616109 5,329,946 -34,719 -0.65 33,046 -34.75 0.0021
2024-05-13 2024-03-31 13F FULCRUM THERAPEUTICS COM 359616109 5,364,665 -319,950 -5.63 50,642 31.98 0.0034
2024-02-13 2023-12-31 13F FULCRUM THERAPEUTICS COM 359616109 5,684,615 -290,801 -4.87 38,371 44.63 0.0029
2023-11-13 2023-09-30 13F FULCRUM THERAPEUTICS COM 359616109 5,975,416 421,676 7.59 26,531 44.76 0.0023
2023-08-11 2023-06-30 13F FULCRUM THERAPEUTICS COM 359616109 5,553,740 -602,588 -9.79 18,327 4.46 0.0015
2023-08-11 2023-03-31 13F/A-1 FULCRUM THERAPEUTICS COM 359616109 6,156,328 922,603 17.63 17,546 -53.95 0.0016
2023-05-11 2023-03-31 13F FULCRUM THERAPEUTICS COM 359616109 6,156,328 922,603 17,546 0.0016
2023-02-13 2022-12-31 13F FULCRUM THERAPEUTICS COM 359616109 5,233,725 -2,571,917 -32.95 38,102 -39.66 0.0038
2022-11-10 2022-09-30 13F FULCRUM THERAPEUTICS COM 359616109 7,805,642 1,678,411 27.39 63,147 110.33 0.0066
2022-08-12 2022-06-30 13F FULCRUM THERAPEUTICS COM 359616109 6,127,231 30,753 0.50 30,023 -79.18 0.0030
2022-05-13 2022-03-31 13F FULCRUM THERAPEUTICS COM 359616109 6,096,478 14,161 0.23 144,182 34.00 0.0115
2022-02-14 2021-12-31 13F FULCRUM THERAPEUTICS COM 359616109 6,082,317 37,554 0.62 107,596 -36.90 0.0079
2022-02-14 2021-09-30 13F/A-1 FULCRUM THERAPEUTICS COM 359616109 6,044,763 3,665,282 154.04 170,523 583.82 0.0135
2021-11-15 2021-09-30 13F FULCRUM THERAPEUTICS COM 359616109 6,044,763 3,665,282 170,523 0.0135
2021-08-13 2021-06-30 13F FULCRUM THERAPEUTICS COM 359616109 2,379,481 -36,250 -1.50 24,937 -12.37 0.0020
2021-05-14 2021-03-31 13F FULCRUM THERAPEUTICS COM 359616109 2,415,731 665,995 38.06 28,458 38.89 0.0024
2021-02-08 2020-12-31 13F FULCRUM THERAPEUTICS COM 359616109 1,749,736 -86,500 -4.71 20,489 40.71 0.0018
2020-11-13 2020-09-30 13F FULCRUM THERAPEUTICS COM 359616109 1,836,236 -14,316 -0.77 14,561 -56.98 0.0015
2020-08-24 2020-06-30 13F/A-1 FULCRUM THERAPEUTICS COM 359616109 1,850,552 68,101 3.82 33,847 59.04 0.0037
2020-08-13 2020-06-30 13F FULCRUM THERAPEUTICS COM 359616109 1,850,552 68,101 33,847 831.5217
2020-05-14 2020-03-31 13F FULCRUM THERAPEUTICS COM 359616109 1,782,451 81,700 4.80 21,282 -23.19 0.0029
2020-02-07 2019-12-31 13F FULCRUM THERAPEUTICS COM 359616109 1,700,751 207,867 13.92 27,706 193.56 0.0031
2019-11-13 2019-09-30 13F FULCRUM THERAPEUTICS COM 359616109 1,492,884 1,492,884 9,438 0.0011
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.